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and JoAnne Reifsnyder, Ph.D., ACHPN4
Abstract
Purpose: High symptom burden and hospital mortality among patients with lung cancer argues for early
palliative care intervention. Patient characteristics and discharge dispositions in hospitalized patients with lung
cancer receiving usual care were compared to those referred to a new palliative care service.
Methods: A retrospective database review of all lung cancer discharges receiving usual care (UC) and palliative
care service (PCS) consultation was conducted. Demographics, length of stay, discharge disposition, and mor-
tality were described and compared. Palliative Performance Scale scores were described according to discharge
disposition in the PCS group. Disposition of all patients receiving either chemotherapy or surgery was also
noted.
Results: A total of 1476 hospital discharges with a diagnosis of lung cancer occurred between March 15, 2006
and June 30, 2009. Among all discharges, 9% received chemotherapy and 29% had surgery. The PCS was
consulted for 8% of all lung cancer patients most commonly to address end-of-life-issues. PCS patients were
more likely to be at the end-of-life than UC patients as evidenced by higher hospital mortality (31% versus 7%),
higher intensive care (ICU) mortality (67% versus 16%) and more frequent discharge to hospice (41% versus 7%).
PCS patients were hospitalized a median of 6 days before a referral was made. Hospitalization was significantly
longer for PCS patients (M¼ 16.3 days, p< 0.001) than UC patients (M¼ 8.3 days).
Conclusions: In the first 3 years of a new palliative care initiative consults for lung cancer patients occurred late
in the hospital stay or when death was imminent.
Introduction
As palliative care programs establish their place in theacute care hospital setting, collection and analysis of
clinical, financial and operational metrics is recommended to
measure impact on end-of-life care.1 At both local and na-
tional levels, such analyses permit application of national
benchmarks to guide comparisons between palliative care
and usual acute care. For new palliative care consultation
services, data analysis permits insight into the institution’s
utilization of its services, patient populations most likely to
benefit, practice trends and opportunities for improvement.
In this retrospective database review, characteristics and
selected outcomes were compared for patients with lung
cancer who received palliative care service (PCS) consultation
and those who received usual care (UC). A subset of PCS and
UC patients who received care in the intensive care unit (ICU)
was also compared. Lung cancer was chosen because it was
the most commonly referred diagnosis and is associated with
significant symptom burden at the end of life.2–5
Impact of lung cancer
In 2009 an estimated 159,390 Americans were expected to
die from lung cancer, ranking it the number one cause of
cancer-related death among both men and women.6 Despite
progress in oncology care and patient survival for many
malignancies, lung cancer mortality rates have remained
high, especially among those hospitalized patients requiring
critical care intervention.7,8 Chemotherapy can prolong life in
these patients; however, its effect is generally limited to a few
months and is associated with medical complications, quality
of life issues, and costs.3–5,9,10
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Common symptoms associated with lung cancer include
pain, cough, dyspnea, anorexia, fatigue, hemoptysis, hiccups,
depression, and emotional distress.3–5,10,11 These symptoms
are present in one third to three quarters of patients with lung
cancer, and typically increase in frequency and severity with
disease progression.3–5,12 Unfortunately, the number of
symptoms and impact on the daily lives of patients is unap-
preciated by their physicians.3,10,12,13 In one study of the
characteristics and outcomes of palliative care referrals, re-
searchers found additional symptoms, e.g., delirium, seda-
tion, constipation, that had been neither documented nor
treated by the referring team.12
ICU mortality
While mortality among patients with cancer in critical care
units is not significantly different from non-cancer patients,
patients with cancer are at an increased risk for morbidity
from complications such as sepsis and respiratory failure.8
Inpatient mortality among patients with lung cancer who
receive ICU care is as high as 60%, with 43% of those patients
dying while in the ICU.7
Benefits of palliative care consultation
Improving palliative and end-of-life care has become a na-
tional priority. Increasingly, palliative care is viewed as integral
to high-quality long-term caremanagement across settings and
illnesses regardless of prognosis.14 In 2008, the National Prio-
rities Partnership named improving care for the dying as one of
six national priorities for reforming the health care system.15
The National Comprehensive Cancer Network recommends
the introduction of palliative care to all cancer patients at initial
diagnosis and its integration during treatment to address
symptoms and psychosocial issues.16 Other professional or-
ganizations, e.g., the American Society of Clinical Oncology,
and the National Consensus Project for Quality Palliative Care
are in accord with these recommendations.10 Evidence
emerging from randomized controlled trials supports the ef-
fectiveness of palliative care intervention for symptom relief,
patient/family satisfaction, quality of life and cost.17,18
Palliative care consultation facilitates earlier and more
frequent hospice referral and lower hospital mortality.19–21
Hospice care offers an alternative to life-prolonging inpatient
care and is associated with better symptom control, improved
patient and family satisfaction, and feelings of respect and
inclusion in care decisions.13,19 Hospice utilization by patients
with lung cancer ranges from 25% to 30%, a rate typical of
most cancer types, yet significantly greater than patients with
non-cancer diagnoses.22
The purpose of the present study was to describe the
characteristics of patients with lung cancer referred to a hos-
pital-based palliative care service and compare them to pa-
tients receiving usual care. Data on transition to hospice care
and hospital mortality were compared between groups and
for patients requiring ICU care, chemotherapy, or surgery.
Performance scores contributed data to understand functional
status and expected survival of PCS patients.
Methods
Setting
Thomas Jefferson University Hospital is an academic
medical center with 700 acute care hospital beds. The PCS
includes one oncology nurse practitioner with advanced
palliative care certification. Four physicians (two board-
certified palliative medicine specialists, a geriatrician, and
an internist), one geriatric fellow, and a music practitioner
comprise the rest of the team. The inpatient consultation
service began seeing patient referrals on March 15, 2006.
The PCS provided consultation to inpatient physicians
only, as there is currently no palliative care or hospice unit in
this institution. Referring specialties included oncology, in-
tensive care units (includes medical, surgical, cardiac), and
internal medicine, among others. Physicians consulted the
PCS using an electronic ordering system that prompts a choice
of 1 to 3 referral reasons from the following: advanced care
planning, goals of care discussion, end-of-life issues, psy-
chosocial distress, pain or symptommanagement, andmental
status changes. House staff or nurse practitioners can order
consults, however, the PCS routinely verifies the attending
physician’s consent before seeing the patient. The attending
physician has declined in approximately 2% of all consults.
Study design, sample, and data collection
A retrospective review of data from the PCS and hospital
administrative databases included all discharges with either a
primary or secondary diagnosis of lung cancer during the
study period of March 15, 2006 through June 2009. Lung
cancer diagnosis was determined using ICD-9 codes. The In-
stitutional Review Board approved this study.
Various demographic characteristics were collected on all
patients including: age, gender, and ethnicity. While both
databases yielded information on length of hospital stay, ICU
use, chemotherapy and surgery episodes, and discharge dis-
position, the PCS database provided reasons for consultation,
referring specialty, length of stay relative to PCS consultation
(number of days before, during, and after), and performance
scores.
The Palliative Performance Scale version 2 (PPS) has been
validated as a measure of functional status and predictor of
survival for cancer patients in hospice and inpatient palliative
care settings.23,24 Scores range from 0 (death) through 100
(fully functional) in increments of 10%. The PCS began rou-
tine assessment using the PPS in January 2008. Thus, perfor-
mance score data were extracted from the PCS database for
those patients assessed and collapsed into three categories for
analysis: 20% or less, 30%–50%, and 60% or more. These
categories are consistent with an earlier analysis performed by
Morita et al.25
Statistical analysis
All statistical analyses were conducted using SPSS version
15.0 (SPSS Inc., Chicago, IL). An a of p< 0.05 was used to
indicate significance for all statistical tests in this study.
Differences in demographics and mean length of stay were
compared between the two groups using a two-tailed inde-
pendent samples t test. w2 tests were used to compare differ-
ences in distribution of categorical variables between the
groups, such as patient gender, ethnicity and disposition.
Because of the wide range noted in length of hospital stay,
both mean and median were calculated for comparison. For
the purposes of analysis, discharge dispositions were divided
into the following categories: died, hospice, skilled nursing
facility/rehabilitation transfer, ventilator facility transfer,
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home, and other. The hospice category includes home hos-




There were 1476 discharges with either a primary or sec-
ondary diagnosis of lung cancer during the study period. Of
these, 118 (7.9%) were consulted by the PCS, leaving a sample
of 1358 (92%) in the usual care group. Patient characteristics
for both groups are displayed in Table 1. Nine percent of all
patients received chemotherapy and 29% had a surgical pro-
cedure during hospitalization.
PCS patients were significantly older (M¼ 67.7 years,
standard deviation [SD]¼ 12.7) than usual care patients
(M¼ 64.8 years, SD¼ 11.6, p< 0.01). There were no signifi-
cant differences in gender or ethnicity between groups.
Referral patterns
The most common referring specialty was oncology, ac-
counting for 32 (27%) of the 118 lung cancer referrals to the
PCS. The second and third most frequently referring special-
ties were the ICU (n¼ 30, 25%) and internal medicine (n¼ 21,
18%), respectively. The most common reason for referral was
end-of-life issues (n¼ 68, 57%), followed by goals of care
discussion (n¼ 52, 44%) and advanced care planning (n¼ 27,
23%). Pain and symptom management (18% and 7%, respec-
tively) accounted for smaller percentages of referrals, with
still fewer consults for psychosocial distress (4%) and mental
status changes (3%).
Length of stay, timing of PCS consultation,
and discharge disposition
The length of stay was significantly longer (M¼ 16.31
days, SD¼ 14.61, p< 0.001) for PCS patients than the usual
care group (M¼ 8.28 days, SD¼ 8.96). Hospitalization in
both groups ranged from a minimum of 1 day to maximum
of 102 days. However, median length of stay was also twice
as long for PCS patients (Md¼ 12.5 days) as UC patients
(Md¼ 6 days).
Consults to palliative care were made a median of 6 days
into lung cancer patients’ hospitalization. Patients were
followed by PCS for a median of 4 days, and discharged less
than 2 days after consult concluded.
Discharge disposition for the PCS and usual care groups is
shown in Table 2. The PCS patients (72%, n¼ 84) had a higher
likelihood of being at the end-of-life, i.e., discharged to hos-
pice or died during hospital stay, than those in the usual care
group (12%, n¼ 170).
Nearly a quarter of the patients in each group received ICU
care and 20% of these patients died during the admission
(Table 3). However, more PCS patients in the ICU died (67%
versus 16%) or were discharged to hospice (17% versus 4%),
compared to the usual care group.
Of all hospitalized patients receiving chemotherapy, 8%
died or enrolled in hospice. For patients who had surgery,
11% died or were discharged to hospice.
Palliative Performance Scale scores
Palliative Performance Scale scores were available for 55
(46.6%) patients seen by PCS. Overall, 85% of patients
scored at or below 50%. The discharge disposition of PCS
patients according to PPS score is presented in Table 4.
Patients with a PPS score of 20% or less most often died in
the hospital (67%, n¼ 10). Patients with a PPS score from
30% to 50% were most commonly discharged to hospice
(53%, n¼ 17).
Discussion
This study depicts utilization of a palliative care team
during its early implementation period and may be in-
structive for others pioneering similar efforts. However, a
clear picture of the success or challenge of palliative care’s
integration is limited because existing data sources
only partially reveal the unmet need among usual care
patients.
This hospital database did not provide data on symptom
severity, performance status, or disease stage metrics to
identify usual care patients with palliative care needs.1
However, it did permit identification of patients who received
chemotherapy or surgery during their hospital stay, a possible
indicator of better performance status and ineligibility for
palliative care consultation. If this cohort were eliminated
from the sample on that basis, the PCS was involved in a
larger percentage, i.e., 13% versus 8%, of all eligible patients
with lung cancer. Ultimately, this variable was invalidated as
a marker of palliative care ineligibility when disposition data
revealed that 19% of those who received chemotherapy or
surgery died or chose hospice. While the use of palliative
chemotherapy can offer some benefit without severe toxicity,
these data raise several questions about appropriate goals
and use of health care resources that are worthy of future
research.26
The PCS was utilized for a small percentage of patients
with lung cancer and when used, was consulted late in the
course of hospitalization. Most patients referred died or were
discharged to hospice. These referral patterns reveal a com-
mon misperception among providers that palliative care is
mutually exclusive with life-prolonging care, frequently jus-
tified by the response that their patient is ‘‘not ready
Table 1. Characteristics of Patients with Lung
Cancer: Palliative Care Service
and Usual Care Groups
PCS n¼ 118 Usual n¼ 1358
Mean Age (SD)
Gender
67.6 (12.7) 64.8 (11.6) p¼ 0.009
Male 56 (47%) 634 (47%) NS
Female 62 (53%) 724 (53%)
Ethnicity
Caucasian 72 (61%) 908 (67%) NS
Black 36 (31%) 341 (25%)
Hispanic 0 (0%) 6 (0.4%)
Asian 6 (5%) 60 (4%)
Unknown/Other 4 (3%) 41 (3%)
Percentages are rounded to the nearest whole percent.
PCS, palliative care service; SD, Standard deviation, NS, not
significant.
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yet.’’10(p408S) Late referrals do not prove palliative care needs
were unmet, but may reflect providers’ comfort with
addressing palliative care needs without specialty referral
before the end of life. Other explanations for nonreferral or
late referrals may include lack of familiarity with palliative
care among providers, insufficient or ineffective marketing, or
refusal by patients or their families.
Hospital data are not available to permit comparisons of
symptom prevalence and severity between groups. Patients
were referred to PCS for end-of-life issues twice as often as for
pain or symptom management despite evidence of high rates
of pain and other symptoms in this population.3–5,12 How-
ever, referrals for psychosocial distress or mental status
changes were uncommon. Usual care patients may have re-
ceived symptom palliation from the primary hospital team,
the hospital pain service or psychosocial providers. However,
previous research suggests that patients’ symptoms are often
underrecognized and undertreated.3,12,13
Studies using a variety of designs for measuring clinical
metrics such as pain and symptom scores, patient satisfaction,
ICU mortality, or costs of care have shown benefits of inpa-
tient palliative care teams.12,17,18,21 The present study does not
report prevalence and severity of pain and symptoms or the
success of the PCS at ameliorating these complications of
lung cancer. However, further standardization of symptom
assessment is a goal for the PCS.
The PCS facilitated higher rates of hospice referral com-
pared to usual care. The strength of these conclusions is lim-
ited by the sample sizes for the PCS group and the ICU
subgroup, as well as inability to control for disease stage,
illness acuity, or comorbidities.
The Palliative Performance Scale scores in the PCS sample
were consistent with scores among seriously ill patients in
other studies.23–25 Overall, 85% of patients scored at or below
50%, a score that is associated with a high likelihood of death
in 6 months thereby connoting hospice eligibility.23 Scores
were less than 20% in more than one quarter of cases, pre-
dicting survival of 1 week. The majority of these patients died
in hospital whereas those with scores that fell in the 30%–50%
range were most often discharged with hospice, indicating
some expected survival beyond hospital discharge. An inpa-
tient hospice unit in this hospital would support the sickest
patients with comfort-based care and family-focused services.
These institutional transfers would open acute care beds
and resources, especially in ICU, for patients more likely to
benefit.
The findings of the present study, although limited by the
relatively small PCS sample, support previous findings of
high mortality rates in patients with lung cancer who receive
critical care.7,8 Overall, inpatient mortality among patients
receiving ICU care was 20% in this study. However, mortality
among PCS patients was higher (67%). More analysis is nee-
ded to determine reasons for this disparity, which previous
research has suggestedmay be a result of unaccounted patient
and hospital characteristics.27
The retrospective design and disparate group sizes limit
this study’s conclusions about both the effectiveness of the
PCS and whether certain markers, such ICU care or low PPS
scores are accurate predictors of mortality. It is also likely, that
since the PCS is relatively new, and referral practices are
evolving, that these data do not reflect more recent referral
trends. Nonetheless, the findings sufficiently support evi-
dence of gaps in end-of-life care for patients with lung cancer
to warrant further initiatives by our nascent palliative care
team. Planned revisions in processes of care will include
routine data collection on symptom assessment, interven-
tions, and outcomes of PCS referrals, e.g., pain and symptom
scores, establishment of patient’s goals of care, transition
away from life-prolonging technology. Patient, family, and
provider satisfaction with PCS services will further inform
these efforts.
Education of all providers on the complex care needs of lung
cancer patients, the scope of palliative care services, and its
potential benefits is needed. The use of referral criteria for
palliative care consultation can serve as both an education,
screening, and marketing tool and will be the aim of a future
performance improvement project. Development of a long-
termcaremanagementmodel in collaborationwith lung cancer
care providers has the potential to promote earlier case find-
ing.17 Continued efforts to integrate the PCS earlier and more
frequently for patients with chronic and/or life-threatening
Table 2. Discharge Disposition: Palliative Care Service versus Usual Care Groups
Died Hospice SNF/Rehab Ventilator facility Home Other Total
Usual 84 (6) 86 (6) 180 (13) 0 (0) 975 (72) 33 (2) 1358 (100)
PCS 36 (31) 48 (41) 10 (8) 3 (3) 20 (17) 1 (1) 118 (100)
Total 120 (8) 134 (9) 190 (13) 3 (<1) 995 (67) 34 (2) 1476 (100)
Numbers in parentheses represent percent of row total. Percentages are rounded to the nearest whole percent.
PCS, palliative care service; SNF, skilled nursing facility.
Table 3. Discharge Disposition Among Palliative
Care and Usual Care Groups receiving






Died 20 (67) 51(16)
Hospice 5 (17) 12 (4)
Skilled nursing or
rehabilitation facility
1 (3) 75 (24)
Ventilator facility 3 (10) 0 (0)
Home 1 (3) 173 (55)
Other 0 (0) 5 (2)
Total 30 (100) 317 (100)
Numbers in parentheses represent percent of column total
rounded to nearest whole percent.
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illnesses, particularly those with high symptom burden, is
consistent with the purpose of palliative care and supports
national goals to improve end-of-life care.15,28
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